The medical potential of therapeutic stem cells is virtually inexhaustible, e.g. in form of personalized medicinal products for individual therapies. Additionally, stem cell-based off-the-shelf pharmaceuticals could be used to treat general diseases. This would significantly reduce production costs and would make stem cell therapies accessible to almost every patient. Oxacell AG provides effective solutions for all applications.

Individual Therapies (personalized medicine)

Body’s own (autologous) adipose-derived stem cells (ASCs) can be used to treat disease and medical conditions of the locomotory such as arthrosis, muscle, ligament and tendon injuries as well as other joint complaints. They are ideally suited for soft tissue reconstruction (e.g. breast augmentations as an alternative to silicone) as part of a technique called cell-assisted lipotransfer (CAL). Additionally, ASCs can be applied for the treatment of damaged skin and subcutaneous fatty tissue after burns or irradiation

Stem cells for Everybody

Conventional therapies with foreign (allogenic) cells or organs can induce an inflammatory response in the recipient. We know this phenomenon as rejection reaction e.g. after organ transplantation. Mesenchymal stem cells, however, are weakly immunogenic (immune-privileged) meaning they are not recognized by the immune system due to a lack of specific surface receptors. Therefore, thousands of patients can easily be treated with a fat graft from a single donor.
The development of modern therapies is only just beginning but the possibilities for stem cell applications seem unlimited.

Systemic Therapies:

  • Autoimmune diseases (type 1 diabetes, rheumatic diseases)
  • Neurological disorders (Parkinson, Multiple sclerosis, Alzheimer’s)
  • Cardiomyopathies (myocardial infarction)
  • Stroke
  • Cancer treatments (leukemia etc.)
  • Peripheral arterial occlusive disease, circulatory disorders
  • Lifestyle treatments (anti-aging, beauty, etc.)

Local Therapies:

  • Joint disease (cartilage damage, arthrosis, arthritis)
  • Tendonitis and overuse injuries
  • Fracture diseases (pseudarthroses)
  • Spinal cord injury
  • Soft tissue reconstruction applying cell assisted lipotransfer (CAL): Breast reconstruction after breast surgery, breast augmentation (alternative to silicone)
  • Skin damage after irradiation
  • Chronic wounds
  • Facelift with stem cells
  • Erectile Dysfunction

Possible clinical applications of adipose-derived adult stem cells:

Innovative therapies based on stem cells are on the rise worldwide. Due to tremendous efforts in basic research, our insight into the biological function and operation of our body increases daily. OXACELL® AG goal is the utilization of this knowledge for the development novel therapies (ATMPs, advanced therapy medicinal products). The steady increase in approved ATMPs for the treatment of various disease worldwide clearly supports the excellent medical potential of these new approaches.
The term ATMP includes gene therapy medicinal products, somatic cell therapy medicinal products as well as tissue engineered products. Stem cell-based medicinal products belong to the ladder category.


Adult stem cells are considered the bearer of hope for regenerative medicine. 

Intensive research is aimed at the medical application of stem cells for the renewal of old or diseased tissues. As a matter of fact, a large amount of scientific publications already demonstrated the regenerative and immune-modulatory properties of adipose-derived stem cells (ASCs). Moreover, more than 200 clinical studies using ASCs are conducted worldwide. The indications are as diverse as the patients involved.

In 2015, the first stem cell-based ATMP was approved in Europe. This product is designated for the restoration of the eyesight after corneal injuries, demonstrating the enormous performance of modern stem cell therapies. Furthermore, this example impressively illustrates the feasibility to design clinical therapies based on stem cells according to the pharmaceutical standards.

Copyright © 2018 Oxacell AG | Helene-Lange-Straße 12, 14469 Potsdam | Tel. +49 (0)331 - 24 34 63 96 | e-mail: